The Idd5 locus for autoimmune diabetes in nonobese diabetic (NOD) mice has been mapped to the proximal half of chromosome 1 and appears to include two loci, Idd5.1 and Idd5.2, Idd5.1 being a candidate homolog of the human IDDM12 locus. Using new recombinant congenic lines, we have reduced the Idd5.1 interval to 5 cM at most, between D1Mit279 and D1Mit19 (not included). This interval now excludes the Casp8 and Cflar (Flip) candidate genes. It still retains Cd28 and Ctla4 and also includes Icos (inducible costimulator). The previously reported differential expression of Ctla4, which is induced at a lower level in NOD than in B6-activated T-cells, was found independent of Idd5.1 itself because Ctla4 expression was induced at a low level in T-cells from Idd5.1-congenic mice. The Idd5.1 locus protected against both spontaneous and cyclophosphamide-induced diabetes, but it did not prevent inflammatory infiltration of the islets of Langerhans. Furthermore, diabetogenic precursor spleen cells from prediabetic NOD and Idd5.1-congenic mice were equally capable of transferring diabetes to immunodeficient NOD.scid/scid recipient mice. The Idd5.1 locus might affect a late event of disease development, subsequent to the onset of insulitis and possibly taking place in the islets of Langerhans.

The Idd5 locus was initially mapped to the proximal half of murine chromosome 1 (1,2). It was associated with susceptibility to both spontaneous and cyclophosphamide-induced diabetes (1) and also with inflammatory infiltration of the islets of Langerhans, including periinsulitis and insulitis (2,3). To further study the Idd5 locus, we generated NOD mice congenic for a 30-cM interval of C57BL/6 (B6) origin extending from D1Mit478 to D1Mit26 (NOD-B6.Bcl2) (see Table 1). An intercross between heterozygous mice was performed at the 7th generation of backcrossing to confirm the existence of Idd5 and to initiate its fine mapping. Progeny mice were genotyped, and development of spontaneous diabetes in female mice was monitored for 9 months. Incidence of diabetes was markedly influenced by genotypes at the D1Mit18 (Fig. 1A) and D1Mit5 (not shown) markers and at the proximal end of the selected region, but not at D1Mit44 and the more distal loci (not shown). The protective effect of the B6 haplotype was partially dominant (P = 0.008). Similar results were obtained when diabetes was induced by injection of cyclophosphamide in progeny mice from heterozygous parents at the 11th generation of backcross. Genotypes at D1Mit18 (Fig. 1B) and D1Mit5 but not at more distal loci (not shown) significantly affected susceptibility to this form of diabetes, which is otherwise specifically induced in NOD mice (4). Interestingly, the protective effect of the B6 haplotype was dominant (P = 0.008).

The Idd5 interval was recently circumscribed by the use of congenic and recombinant congenic mice (5). Evidence was also obtained for two loci, Idd5.1 and Idd5.2, that were closely linked and both predisposing to autoimmune diabetes. Importantly, the human synteny equivalent to Idd5.1 is on chromosome 2q33 and overlaps the IDDM12 locus for human type 1 diabetes (5).

Here, we have further narrowed down the Idd5.1 interval using new recombinant congenic lines. The R1 line harbored a segment of B6 origin (Table 1) between D1Mit478 and D1Mit178 (both markers included) that overlaps with that defined by the Idd5R467 recombinant congenic strain (5). As shown on Fig. 2A, R1 mice had a significantly reduced incidence of spontaneous diabetes (P = 1 × 10−5) that was approximately half of that of their NOD littermates. These mice were also protected from diabetes induced by cyclophosphamide (P = 9 × 10−5) (Fig. 3A). Additional recombinant congenic strains were selected (Table 1). The R6 and R16.14 subcongenics retained various segments of B6 origin in the proximal part of the R1 segment. These mice had an incidence of diabetes similar to that of NOD mice (Fig. 2B). Conversely, the R67 and R39 recombinants, which retained a B6 chromosomal segment in the distal part of the R1 interval, were protected from diabetes (P < 1 × 10−5 for both R67 and R39) (Fig. 2A).

Altogether, we now map the Idd5.1 locus to the interval defined by the R39 recombinant congenic strain. The centromeric boundary of this interval lies between the D1Mit279 and D1Mit302/D1Mit22 markers. This location therefore rules out the segment comprising the region between D1Mit478 and D1Mit302/D1Mit22 that was previously part of the Idd5.1 interval (5). The distal boundary of R39 is more loosely limited and maps between the D1Mit178 and D1Mit19 markers, and thus it cannot be distinguished with currently available markers from the distal boundary defined by the Idd5R467 line (5). As a result, the size of the Idd5.1 interval ranges from 3.0 to 5.0 cM.

The newly restricted Idd5.1 locus excludes Cflar and Casp8, two important candidate genes (5). It still retains the two costimulatory receptors Cd28 and Ctla4. No coding polymorphism between NOD and B6 was identified in these two genes (6; S.-E.L.-C., O.B., unpublished observations). By endonuclease restriction of both genomic DNA (Southern blot analysis) and polymerase chain reaction (PCR)-amplified intronic sequences, restriction fragment–length polymorphism (RFLP) between the two strains were characterized (see research design and methods). Typing of recombinant haplotypes for these RFLPs allowed for the placement of Ctla4 telomeric to Cd28.

Such noncoding polymorphisms could have a regulatory function that results in differential expression of Ctla4 or Cd28. Indeed, Ctla4 is induced in activated T-cells at a lower level in NOD than in B6 mice (6) (Fig. 4). This is consistent with a contribution of the Ctla4 gene to the autoimmune predisposition of NOD mice, because Ctla4 is viewed as a negative regulator of T-cell activation (7), and Ctla4-null mice develop early lethal pleiotropic dysimmune manifestations (8). However, activated T-cells from R67 congenic mice expressed Ctla4 at a low level, like their NOD parent (Fig. 4). The decrease of inducible Ctla4 expression in NOD T-cells is therefore unlikely to be determined at the Ctla4 locus itself or at a closely linked gene included in the Idd5.1 interval.

Inducible costimulator (Icos), which facilitates T-cell activation, is another important regulatory molecule homologous to Ctla4 and Cd28 (9). The Icos gene was located in the vicinity of Cd28 and Ctla4 (10). A polymorphic dinucleotide repeat was identified in the second intron of the Icos sequence. Using this marker, Icos was located in the R39 interval, telomeric to Cd28 and tightly linked to Ctla4, D1Nds25, and D1Mit249. Because the expression and nucleotide sequence of Icos have not yet been characterized in NOD mice, it is an important candidate that warrants additional investigation.

The Idd5 region defined by the large Idd5R8 segment did not affect inflammatory infiltration of the islets of Langerhans, as determined from tissue sections stained with hematoxylin and eosin (5). This was also the case for the smaller Idd5.1 interval harbored by the R67 recombinant congenic line (data not shown). Transfer experiments were performed to determine whether diabetes protection occurred before or after the entry of these inflammatory cells into the islets of Langerhans. Prediabetic spleen cells from NOD or R67 donor mice were infused into immunodeficient NOD.scid/scid recipient mice. As shown in Fig. 3B, spleen cells from both donors were equally capable of transferring diabetes. This finding is consistent with an association of Idd5.1 with resistance to induction of diabetes by cyclophosphamide, because this drug is thought to require the presence of insulitis to be effective. The Idd5.1 gene might therefore act at a late stage of disease development, subsequent to the onset of insulitis and possibly taking place in the islets of Langerhans. For example, it might affect the late differentiation of inflammatory cells into cytotoxic cells or modulate β-cell sensitivity to autoimmune aggression.

With the rapid progress of the Mouse Genome Sequencing program, the current size of the Idd5.1 interval makes the identification of the Idd5.1 gene a feasible task. Construction and sequencing of a contig covering the region of interest should be carried out concurrently with the search for DNA polymorphisms. Knowing the site of expression of Idd5.1 should be helpful in testing correlations between these polymorphisms and quantitative variation of candidate gene expression. Such quantitative variation could be the basis of Idd5.1 if the pathogenic DNA alteration maps outside the coding region.

Mice and genetic analysis.

NOD and C57BL6/J (B6) mice were bred in our animal facilities under specific pathogen-free conditions, in keeping with the European Union legislation on animal care. NOD mice congenic for the portion of chromosome 1 derived from the B6 strain and comprising the region between D1Mit478 and D1Mit26 (both markers included) were bred by iterative backcrossing with NOD parents and by genotypic selection of heterozygous mice at each generation. The R1 homozygous line was established by appropriate sister-brother matings at the 10th generation of backrossing. Other recombinant congenic lines were derived from the R1 line after a large (1,490 progeny mice) backcross of R1 heterozygous mice with NOD parents. The R16.14 was a secondary recombinant derived from one of these primary recombinant congenic lines.

Diabetes assessment and transfer experiments.

Development of spontaneous diabetes was followed weekly by testing urinary levels of glucose with glukotest (Roche). Mice were classified as diabetic after producing two consecutive tests of 3+ or higher. Diabetes was also induced in 8- to 10-week-old mice by two intraperitoneal injections of cyclophosphamide (200 mg/kg) on days 0 and 14. Diabetes onset was then monitored daily for 30 days. For transfer experiments, donor spleen cells were prepared from 10-week-old prediabetic NOD or R67 congenic mice. T-cells were enumerated with a fluorescein isothiocyanate–labeled anti-CD3 monoclonal antibody (mAb) (clone 145-2C11). An equivalent of 2 × 106 T-cells was injected intravenously into immunodeficient NOD.scid/scid recipient mice. Incidences of diabetes were compared with the log-rank test.

Polymorphisms and genetic map.

Microsatellite markers that are polymorphic between NOD and B6 were drawn from the Massachusetts Institute of Technology database (11) (see website at www-genome.mit.wi.edu) and, for D1Nds25 and D1Nds27, from the recent report by Hill et al. (5). Orders and distances between loci were those of the Mouse Genome Database (12) (see website at www.informatics.jax.org). Previously unordered markers in the Idd5 interval were ordered by the typing of recombinant haplotypes and minimization of the number of recombination events.

RFLPs of Ctla4 and Cd28 genes between NOD and B6 strains were typed by Southern blot hybridization with cDNA probes, using standard protocols (13). The Ctla4 probe was a partial cDNA probe (position 324–922, Genbank accession number X05719). An RFLP was identified with XbaI (14 kb in NOD, 8 kb in B6). The Cd28 probe was also a partial cDNA probe (position 60–676, Genbank accession number M34563). An RFLP was identified with BglII (3.2 kb in NOD, 0.8 kb in B6).

PCR-RFLPs were also characterized in the Ctla4 gene by amplification of genomic DNA using oligonucleotide primers (forward and reverse: position 324–343 and 922–901 of the cDNA, sequence CACAGAGAAGAATACAGTGG and GCTCTCTGTTCTGCTCCTTAGC, respectively) located in the second and third exons, respectively. The resulting PCR product (∼2 kb) was cut with HinfI and migrated on a 2% agarose gel. A polymorphic fragment between NOD (∼240 nt) and B6 (∼220 nt) was visualized by ethidium bromide staining.

A CA/GA complex repeat was identified in the second intron of the Icos gene by inspection of available sequence data (Genbank accession number AF327185). It was amplified with the following primers: forward ATCTCCAAGACTTCTCCCAC and reverse AATGAGCTGCTGTCAACTAC. Polymorphic PCR products were separated by agarose gel electrophoresis.

Typing of recombinant haplotypes for the above polymorphisms led to this most likely order:

\[cen-(\mathit{D}1\mathit{Mit}302{/}\mathit{D}1\mathit{Mit}22)-(\mathit{D}1\mathit{Mit}479{/}\mathit{Cd}28)-\]
\[(\mathit{D}1\mathit{Nds}25{/}\mathit{Ctla}4{/}\mathit{Icos}{/}\mathit{D}1\mathit{Mit}249)-\mathit{D}1\mathit{Mit}301-tel.\]

T-cell activation and Ctla4 staining.

Cell suspensions were prepared from spleens of 6-week-old mice and cultured at 2 × 106 cells/ml with soluble anti-CD3 mAb (clone 145-2C11) at 0.5 μg/ml. After 48 h, cells were harvested, fixed with 2.5% formaldehyde, permeabilized with 0.1% saponin, and stained with a phycoerythrin-conjugated anti-Ctla4 mAb (clone UC10-4F10; Pharmingen). Flow cytometry was performed on a FACScan (Becton Dickinson). At least 30,000 events were acquired and analyzed with CellQuest software. Ctla4 expression in activated T-cells was detected by gating large blast cells using forward and side-scatter profiles.

FIG. 1.

Influence of the D1Mit18 marker on the cumulative frequency of spontaneous (A) and cyclophosphamide-induced (B) diabetes in intercrossed congenic mice. Heterozygous mice at the 7th (A) or 11th (B) generation of backcrossing for the [D1Mit18-D1Mit26] interval were intercrossed. Progeny mice were genotyped for markers spanning the interval and were monitored for development of spontaneous (A) or cyclophosphamide-induced (B) diabetes.

FIG. 1.

Influence of the D1Mit18 marker on the cumulative frequency of spontaneous (A) and cyclophosphamide-induced (B) diabetes in intercrossed congenic mice. Heterozygous mice at the 7th (A) or 11th (B) generation of backcrossing for the [D1Mit18-D1Mit26] interval were intercrossed. Progeny mice were genotyped for markers spanning the interval and were monitored for development of spontaneous (A) or cyclophosphamide-induced (B) diabetes.

FIG. 2.

Cumulative incidence of spontaneous diabetes in resistant (A) and sensitive (B) recombinant congenic mice and in NOD control mice.

FIG. 2.

Cumulative incidence of spontaneous diabetes in resistant (A) and sensitive (B) recombinant congenic mice and in NOD control mice.

FIG. 3.

A: Resistance of Idd5.1 (R1) congenic mice (•) to cyclophosphamide-induced diabetes compared with NOD controls (□). B: Transfer of diabetes into immunodeficient NOD.scid/scid mice by diabetogenic precursor spleen cells from NOD (□) and R67 congenic mice (•).

FIG. 3.

A: Resistance of Idd5.1 (R1) congenic mice (•) to cyclophosphamide-induced diabetes compared with NOD controls (□). B: Transfer of diabetes into immunodeficient NOD.scid/scid mice by diabetogenic precursor spleen cells from NOD (□) and R67 congenic mice (•).

FIG. 4.

Ctla4 expression in activated T cells from NOD (dotted line), B6 (thin line) and R67 (thick line) mice. Spleen cells were stimulated for 2 days by ligation of CD3. Cells were then harvested, permeabilized, and stained with a phycoerythrin-tagged anti-Ctla4 mAb and analyzed by fluorocytometry. These profiles are representative of three NOD mice (mean ± SD, 60.0 ± 1.3% of Ctla4-positive cells), three B6 (80.5 ± 1.2) and four R67 (55.1 ± 1.7). The differences between B6 and NOD or B6 and R67 were significant (P value of Student’s t test 4 × 10−5 and 4 × 10−6, respectively). Two additional experiments yielded similar results.

FIG. 4.

Ctla4 expression in activated T cells from NOD (dotted line), B6 (thin line) and R67 (thick line) mice. Spleen cells were stimulated for 2 days by ligation of CD3. Cells were then harvested, permeabilized, and stained with a phycoerythrin-tagged anti-Ctla4 mAb and analyzed by fluorocytometry. These profiles are representative of three NOD mice (mean ± SD, 60.0 ± 1.3% of Ctla4-positive cells), three B6 (80.5 ± 1.2) and four R67 (55.1 ± 1.7). The differences between B6 and NOD or B6 and R67 were significant (P value of Student’s t test 4 × 10−5 and 4 × 10−6, respectively). Two additional experiments yielded similar results.

TABLE 1

Mapping the idd5.1 interval with congenic and recombinant congenic lines

MarkerGeneGenetic distance (cM)*MGD distanceNOD.B6-Bcl2R1R6R16.14R67R39
D1Mit213  — 25.7 NOD NOD NOD NOD NOD NOD 
D1Mit478  0.18 (4/2274) 30.5 B6 B6 B6 NOD NOD NOD 
D1Mit18  2.2 (51/2274) 29.7 B6 B6 B6 NOD NOD NOD 
D1Mit530  0.31 (7/2274) 32.1 B6 B6 B6 B6 NOD NOD 
D1Mit74  0.35 (8/2274) 31.3 B6 B6 B6 B6 NOD NOD 
D1Mit414  0.13 (3/2274) 32.1 B6 B6 B6 B6 B6 NOD 
 Cflar — 30.1 §  —   — 
D1Nds27 Casp8 — 30.1 B6 B6 — B6 B6 NOD 
D1Mit161  0.09 (2/2274) 27.0 B6 B6 NOD B6 B6 NOD 
D1Mit279  0.22 (5/2274) 33.3 B6 B6 NOD B6 B6 NOD 
D1Mit302  0 (0/2274) 32.8 B6 B6 NOD NOD B6 B6 
D1Mit22  0.09 (2/2274) 32.8 B6 B6 NOD NOD B6 B6 
D1Mit479  0.11 (2/1811) 32.8 B6 B6 NOD NOD B6 B6 
 Cd28 — 30.1 B6 B6 NOD NOD B6 B6 
D1Nds25  — — B6 B6 NOD NOD B6 B6 
 Ctla4 — 30.1 B6 B6 NOD NOD B6 B6 
 lcos — 32.0 B6 B6 NOD NOD B6 B6 
D1Mit249  0 (0/1811) 32.8 B6 B6 NOD NOD B6 B6 
D1Mit301  0.55 (10/1811) 32.8 B6 B6 NOD NOD B6 B6 
D1Mit303  0.66 (12/1811) 34.8 B6 B6 NOD NOD B6 B6 
D1Mit300  0 (0/1811) 32.8 B6 B6 NOD NOD B6 B6 
D1Mit480  0.11 (2/1811) 32.8 B6 B6 NOD NOD B6 B6 
D1Mit5  0.50 (9/1811) 32.8 B6 B6 NOD NOD B6 B6 
D1Mit156  0 (0/1811) 32.8 B6 B6 NOD NOD B6 B6 
D1Mit21  1.0 (8/784) 32.8 B6 B6 NOD NOD B6 B6 
D1Mit178  1.8 (14/784) 34.8 B6 B6 NOD NOD B6 B6 
D1Mit19  5.4 (18/334) 36.9 B6 NOD NOD NOD NOD NOD 
 Nramp — 39.2  — — — — — 
D1Mit44  2.4 (8/334) 50.3 B6 NOD NOD NOD NOD NOD 
D1Mit48  3.3 (11/334) 54.0 B6 NOD NOD NOD NOD NOD 
D1Mit11  1.5 (5/334) 58.7 B6 NOD NOD NOD NOD NOD 
 Bcl2 0.9 (3/334) 59.8 B6 NOD NOD NOD NOD NOD 
D1Mit26  5.7 (19/334) 62.1 B6 NOD NOD NOD NOD NOD 
D1Mit30   70.0 NOD NOD NOD NOD NOD NOD 
MarkerGeneGenetic distance (cM)*MGD distanceNOD.B6-Bcl2R1R6R16.14R67R39
D1Mit213  — 25.7 NOD NOD NOD NOD NOD NOD 
D1Mit478  0.18 (4/2274) 30.5 B6 B6 B6 NOD NOD NOD 
D1Mit18  2.2 (51/2274) 29.7 B6 B6 B6 NOD NOD NOD 
D1Mit530  0.31 (7/2274) 32.1 B6 B6 B6 B6 NOD NOD 
D1Mit74  0.35 (8/2274) 31.3 B6 B6 B6 B6 NOD NOD 
D1Mit414  0.13 (3/2274) 32.1 B6 B6 B6 B6 B6 NOD 
 Cflar — 30.1 §  —   — 
D1Nds27 Casp8 — 30.1 B6 B6 — B6 B6 NOD 
D1Mit161  0.09 (2/2274) 27.0 B6 B6 NOD B6 B6 NOD 
D1Mit279  0.22 (5/2274) 33.3 B6 B6 NOD B6 B6 NOD 
D1Mit302  0 (0/2274) 32.8 B6 B6 NOD NOD B6 B6 
D1Mit22  0.09 (2/2274) 32.8 B6 B6 NOD NOD B6 B6 
D1Mit479  0.11 (2/1811) 32.8 B6 B6 NOD NOD B6 B6 
 Cd28 — 30.1 B6 B6 NOD NOD B6 B6 
D1Nds25  — — B6 B6 NOD NOD B6 B6 
 Ctla4 — 30.1 B6 B6 NOD NOD B6 B6 
 lcos — 32.0 B6 B6 NOD NOD B6 B6 
D1Mit249  0 (0/1811) 32.8 B6 B6 NOD NOD B6 B6 
D1Mit301  0.55 (10/1811) 32.8 B6 B6 NOD NOD B6 B6 
D1Mit303  0.66 (12/1811) 34.8 B6 B6 NOD NOD B6 B6 
D1Mit300  0 (0/1811) 32.8 B6 B6 NOD NOD B6 B6 
D1Mit480  0.11 (2/1811) 32.8 B6 B6 NOD NOD B6 B6 
D1Mit5  0.50 (9/1811) 32.8 B6 B6 NOD NOD B6 B6 
D1Mit156  0 (0/1811) 32.8 B6 B6 NOD NOD B6 B6 
D1Mit21  1.0 (8/784) 32.8 B6 B6 NOD NOD B6 B6 
D1Mit178  1.8 (14/784) 34.8 B6 B6 NOD NOD B6 B6 
D1Mit19  5.4 (18/334) 36.9 B6 NOD NOD NOD NOD NOD 
 Nramp — 39.2  — — — — — 
D1Mit44  2.4 (8/334) 50.3 B6 NOD NOD NOD NOD NOD 
D1Mit48  3.3 (11/334) 54.0 B6 NOD NOD NOD NOD NOD 
D1Mit11  1.5 (5/334) 58.7 B6 NOD NOD NOD NOD NOD 
 Bcl2 0.9 (3/334) 59.8 B6 NOD NOD NOD NOD NOD 
D1Mit26  5.7 (19/334) 62.1 B6 NOD NOD NOD NOD NOD 
D1Mit30   70.0 NOD NOD NOD NOD NOD NOD 
*

Intermarker distance determined from the ratio of recombinants to meiosis in our progeny mice;

distance from the centromere (in cM) according to the Mouse Genome Database;

location according to ref. 5;

§

not genotyped.

This work was supported by a grant from the Juvenile Diabetes Foundation and from the Groupement de Recherches et d’Etudes sur les Génomes.

We are grateful to Isabelle Cisse for expert assistance with animal care.

1.
Cornall RJ, Prins JB, Todd JA, Pressey A, DeLarato NH, Wicker LS, Peterson LB: Type 1 diabetes in mice is linked to the interleukin-1 receptor and Lsh/Ity/Bcg genes on chromosome 1.
Nature
353
:
262
–265,
1991
2.
Garchon HJ, Bedossa P, Eloy L, Bach JF: Identification and mapping to chromosome 1 of a susceptibility locus for periinsulitis in non-obese diabetic mice.
Nature
353
:
260
–262,
1991
3.
Garchon HJ, Luan JJ, Eloy L, Bedossa P, Bach JF: Genetic analysis of immune dysfunction in non-obese diabetic (NOD) mice: mapping of a susceptibility locus close to the Bcl-2 gene correlates with increased resistance of NOD T cells to apoptosis induction.
Eur J Immunol
24
:
380
–384,
1994
4.
Yasunami R, Bach JF: Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice.
Eur J Immunol
18
:
481
–484,
1988
5.
Hill NJ, Lyons PA, Armitage N, Todd JA, Wicker LS, Peterson LB: NOD Idd5 locus controls insulitis and diabetes and overlaps the orthologous CTLA4/IDDM12 and NRAMP1 loci in humans.
Diabetes
49
:
1744
–1747,
2000
6.
Colucci F, Bergman ML, Penha-Goncalves C, Cilio CM, Holmberg D: Apoptosis resistance of nonobese diabetic peripheral lymphocytes linked to the Idd5 diabetes susceptibility region.
Proc Natl Acad Sci U S A
94
:
8670
–8674,
1997
7.
Oosterwegel MA, Greenwald RJ, Mandelbrot DA, Lorsbach RB, Sharpe AH: CTLA-4 and T cell activation.
Curr Opin Immunol
11
:
294
–300,
1999
8.
Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW: Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.
Science
270
:
985
–988,
1995
9.
Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, Kroczek RA: ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28.
Nature
397
:
263
–266,
1999
10.
Mages HW, Hutloff A, Heuck C, Buchner K, Himmelbauer H, Oliveri F, Kroczek RA: Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand.
Eur J Immunol
30
:
1040
–1047,
2000
11.
Dietrich WF, Miller J, Steen R, Merchant MA, Damron-Boles D, Husain Z, Dredge R, Daly MJ, Ingalls KA, O’Connor TJ: A comprehensive genetic map of the mouse genome.
Nature
380
:
149
–152,
1996
12.
Blake JA, Eppig JT, Richardson JE, Davisson MT: The Mouse Genome Database (MGD): expanding genetic and genomic resources for the laboratory mouse: the Mouse Genome Database Group.
Nucleic Acids Res
28
:
108
–111,
2000
13.
Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning:
A Laboratory Manual.
2nd ed. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press,
1989

S.-E.L.-C. is currently affiliated with the Department of Molecular and Cellular Engineering, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.

Address correspondence and reprint requests to Henri-Jean Garchon, INSERM U25, Hôpital Necker, 161 rue de Sèvres, 75743 Paris Cedex 15, France. E-mail: garchon@necker.fr.

S.-E.L.-C and O.B. contributed equally to this work.

Received for publication 25 April 2001 and accepted in revised form 12 September 2001.

mAb, monoclonal antibody; PCR, polymerase chain reaction; RFLP, restriction fragment–length polymorphism.